Low-value approvals and high prices might incentivize ineffective drug development

Vinay Prasad, Christopher McCabe, Sham Mailankody

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Drug regulators’ acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.

Original languageEnglish (US)
Pages (from-to)1-2
Number of pages2
JournalNature Reviews Clinical Oncology
DOIs
StateAccepted/In press - May 14 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Low-value approvals and high prices might incentivize ineffective drug development'. Together they form a unique fingerprint.

  • Cite this